Revenue (Tables)

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:

	Year Ended December 31,
Revenue by product (in thousands)	2024		2023		2022
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)	$	141,806	$	105,948	$	81,388
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	15,058		22,203		18,695
Implants sold direct based on contracted rates (c)	31,217		27,484		24,261
Implants sold direct subject to third-party reimbursement (d)	4,603		4,921		3,499
Biopsy kits and instruments - direct bill	2,096		2,087		2,090
Change in estimates related to prior periods (e)	2,529		2,157		2,034
Total MACI implants, kits, and instruments	197,309		164,800		131,967
Epicel
Direct bill (hospital)	36,623		31,574		31,731
NexoBrid (f)	3,292		1,142		667
Total revenue	$	237,224	$	197,516	$	164,365
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents U.S. commercial revenue of NexoBrid for the years ended December 31, 2024 and 2023. In the year ended December 31, 2022, represents revenue based on a percentage of gross profits for sales of NexoBrid to the U.S. Biomedical Advanced Research and Development Authority (“BARDA”), pursuant to the license agreement between the Company and MediWound.

Schedules of Concentration of Credit Risk

The Company’s total revenue and accounts receivable concentrations from a single customer consisted of the following:

For the year ended and as of	Revenue		Accounts Receivable
December 31, 2023	11	%	13	%
December 31, 2024	11	%	10	%